Targeting the proteasome with bortezomib in multiple myeloma:  update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Bortezomib is the first therapeutic inhibitor of the proteasome that has demonstrated a significant clinical response in patients with otherwise refractory or rapidly advancing disease. Bortezomib has received US Federal Drug Administration approval for the treatment of the hematologic malignancies such as multiple myeloma and mantle cell lymphoma. Herein, the use of bortezomib as an upfront therapy, as an induction regimen before stem-cell transplantation and as maintenance therapy in the treatment of multiple myeloma is discussed.
Translational Genomics Section, Medical Oncology Branch, National Cancer Institute, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. driscollj@mail.nih.gov
James J
JJ
Driscoll
Jason
J
Burris
Christina M
CM
Annunziata
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D060828:Induction Chemotherapy; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000379:methods
D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib
J Clin Oncol. 2005 May 20;23(15):3412-20
15809451
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
Blood. 2002 Mar 1;99(5):1745-57
11861292
Br J Haematol. 2003 Jan;120(1):44-52
12492575
Blood. 2007 Mar 15;109(6):2276-84
17105813
J Clin Oncol. 2010 Apr 20;28(12):2077-84
20308672
Br J Haematol. 2008 May;141(4):512-6
18371113
Leuk Lymphoma. 2007 Oct;48(10):1910-21
17917960
Proc Natl Acad Sci U S A. 1989 Oct;86(20):7751-5
2554287
Lancet Oncol. 2010 Oct;11(10):934-41
20739218
N Engl J Med. 1996 Jul 11;335(2):91-7
8649495
Nat Rev Cancer. 2006 Oct;6(10):776-88
16990855
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
Br J Haematol. 2007 Jul;138(2):176-85
17593024
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Blood. 2010 Aug 5;116(5):679-86
20385792
J Clin Oncol. 2006 Oct 20;24(30):4867-74
17001068
Blood. 2007 Apr 15;109(8):3489-95
17209057
Blood. 2009 Apr 2;113(14):3375-82
19064724
Cancer. 2008 Jun 15;112(12):2720-5
18433012
Br J Haematol. 2005 Jun;129(6):776-83
15953004
N Engl J Med. 2004 Oct 28;351(18):1860-73
15509819
Nature. 2009 Apr 9;458(7239):732-6
19360080
Oncologist. 2006 Jan;11(1):51-61
16401713
Clin Cancer Res. 2010 Aug 15;16(16):4094-104
20682705
Leukemia. 2010 Jul;24(7):1350-6
20508619
Haematologica. 2006 Nov;91(11):1498-505
17043025
Exp Hematol. 2006 Jun;34(6):770-5
16728282
Blood. 2010 Sep 2;116(9):1515-23
20525923
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Cancer Res. 1999 Jun 1;59(11):2615-22
10363983
J Clin Oncol. 2009 Jul 20;27(21):3518-25
19528374
J Clin Oncol. 2007 Oct 1;25(28):4452-8
17785704
Leukemia. 2010 Aug;24(8):1406-11
20535147
J Clin Oncol. 2010 Feb 10;28(5):800-7
20048187
Blood. 2010 Aug 5;116(5):674-5
20688962
J Biol Chem. 1990 Mar 25;265(9):4789-92
2180950
Blood. 2010 May 6;115(18):3655-63
20203260
Exp Hematol. 2009 Jul;37(7):791-8
19487069
Haematologica. 2002 Aug;87(8):846-50
12161361
J Clin Oncol. 2010 Oct 20;28(30):4621-9
20823406
J Clin Oncol. 2007 Jun 10;25(17):2434-41
17485707
Blood. 2010 Apr 8;115(14):2827-34
19965618
N Engl J Med. 2003 May 8;348(19):1875-83
12736280
Blood. 2003 Feb 15;101(4):1530-4
12393500
J Clin Oncol. 1998 Dec;16(12):3832-42
9850028
Haematologica. 2006 Jun;91(6):837-9
16769588
Clin Cancer Res. 2008 Aug 1;14(15):4821-9
18676754
Blood. 2010 May 27;115(21):4168-73
20124509
Nat Rev Drug Discov. 2007 Mar;6(3):181-2
17396289